Clinical scale zinc finger nuclease (ZFN)-driven gene-editing of PD-1 in tumor infiltrating lymphocytes (TIL) for the potential treatment of metastatic melanoma

نویسندگان

  • Joal D Beane
  • Gary K Lee
  • Zhili Zheng
  • Nimisha Gandhi
  • Daniel Abate-Daga
  • Mini Bharathan
  • Mary Black
  • Matthew Mendel
  • Zhiya Yu
  • Sadik H Kassim
  • Smita Chandran
  • Martin Giedlin
  • Dale Ando
  • Ed Rebar
  • Andreas Reik
  • Michael Holmes
  • Philip D Gregory
  • Nicholas P Restifo
  • Steven A Rosenberg
  • Richard A Morgan
  • Steven A Feldman
چکیده

Clinical scale zinc finger nuclease (ZFN)-driven gene-editing of PD-1 in tumor infiltrating lymphocytes (TIL) for the potential treatment of metastatic melanoma Joal D Beane, Gary K Lee, Zhili Zheng, Nimisha Gandhi, Daniel Abate-Daga, Mini Bharathan, Mary Black, Matthew Mendel, Zhiya Yu, Sadik H Kassim, Smita Chandran, Martin Giedlin, Dale Ando, Ed Rebar, Andreas Reik, Michael Holmes, Philip D Gregory, Nicholas P Restifo, Steven A Rosenberg, Richard A Morgan, Steven A Feldman

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

PURPOSE To evaluate the expression of tumor PD-L1 and changes in tumor-infiltrating lymphocyte (TIL) populations in patients with metastatic melanoma treated with targeted MAPK inhibitors. EXPERIMENTAL DESIGN Ninety-three tumors were analyzed from 40 patients treated with a BRAF inhibitor alone (BRAFi; n = 28) or combination of BRAF and MEK inhibitors (Combi; n = 12). Tumors were excised befo...

متن کامل

Expansion and characterization of tumor-infiltrating lymphocytes from human sarcoma

Background Adoptive Cell Transfer (ACT) using Tumor Infiltrating Lymphocytes (TIL) has previously been shown at our institution and others to be an effective treatment for metastatic melanoma, resulting in a 38% response rate [1]. We applied this therapy to other solid tumors that have demonstrated a positive correlation between immune infiltrates and patient outcome [2]. Specifically in sarcom...

متن کامل

Predictive Biomarkers and Personalized Medicine Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients

Purpose: Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) is a promising treatment for metastatic melanoma unresponsive to conventional therapies. We report here on the results of an ongoing phase II clinical trial testing the efficacy of ACT using TIL in patients with metastatic melanoma and the association of specific patient clinical characteristics and the p...

متن کامل

Title Reprogramming of Melanoma Tumor-Infiltrating Lymphocytes to Induced Pluripotent Stem Cells

Induced pluripotent stem cells (iPSCs) derived from somatic cells of patients hold great promise for autologous cell therapies. One of the possible applications of iPSCs is to use them as a cell source for producing autologous lymphocytes for cell-based therapy against cancer. Tumor-infiltrating lymphocytes (TILs) that express programmed cell death protein-1 (PD-1) are tumor-reactive T cells, a...

متن کامل

Clinical results of combined vemurafenib and tumor-infiltrating lymphocyte therapy for metastatic melanoma

Background We previously established the feasibility of Tumor-Infiltrating Lymphocyte (TIL) cell therapy for unresectable metastatic melanoma at our institution[1]. This involves resection of tumor from patients for in vitro TIL generation. Upon satisfactory TIL growth, patients are rendered lymphopenic with non-myeloablative chemotherapy and receive adoptive cell therapy with TIL followed by h...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 2  شماره 

صفحات  -

تاریخ انتشار 2014